These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23732377)

  • 1. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.
    Perman MJ; Lucky AW; Heubi JE; Azizkhan RG
    Arch Dermatol; 2009 Jan; 145(1):95-6. PubMed ID: 19153360
    [No Abstract]   [Full Text] [Related]  

  • 3. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 4. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 5. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 6. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 7. How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation?
    Hay JE
    Nat Clin Pract Gastroenterol Hepatol; 2008 Apr; 5(4):190-1. PubMed ID: 18268522
    [No Abstract]   [Full Text] [Related]  

  • 8. [Metabolic bone diseases: benefits and risks of the treatment].
    Rizzoli R
    Rev Med Suisse; 2009 Jun; 5(207):1299-300. PubMed ID: 19626928
    [No Abstract]   [Full Text] [Related]  

  • 9. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE; Kaptoge S; Reeve J
    N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract]   [Full Text] [Related]  

  • 10. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
    Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ
    J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793
    [No Abstract]   [Full Text] [Related]  

  • 11. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN; Westgeest AA
    N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract]   [Full Text] [Related]  

  • 12. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 16. Seizures associated with zoledronic acid for osteoporosis.
    Tsourdi E; Rachner TD; Gruber M; Hamann C; Ziemssen T; Hofbauer LC
    J Clin Endocrinol Metab; 2011 Jul; 96(7):1955-9. PubMed ID: 21508139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
    Henley D; Kaye J; Walsh J; Cull G
    Intern Med J; 2005 Dec; 35(12):726-8. PubMed ID: 16313549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.